The levonorgestrel IUS (LNG20) that Medicines360 proposes to develop consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir around the vertical stem. The steroid reservoir is covered with a polydimethylsiloxane membrane which controls the release rate of levonorgestrel from the reservoir. The LNG20 reservoir contains 52 mg levonorgestrel; providing an initial release rate of 20 mcg/day. A polypropylene monofilament blue thread is attached to the end of the vertical stem. Please refer to the Investigator’s Brochure for full details on the components of LNG20.
LNG20 is currently being investigated in a multi-center, single-blind randomized trial in Europe to assess the therapeutic equivalence in terms of efficacy and safety compared to Mirena in patients with menorrhagia. Enrollment of 280 subjects was completed in January, 2009 and 50% were randomized to LNG20. Serious Adverse Events collected during the reporting period did not reveal any new safety concerns and did not change the overall risk-benefit evaluation for LNG20. To date, adverse event-related removals of the IUS have occurred in five women (three LNG20, two Mirena). The three LNG20 removals were related to ovarian cysts (one of these three subjects required hospitalization). The two Mirena removals followed development of abdominal and peripheral edema in one subject, and reported nervousness, chest tension, abdominal pain, and hypertension in a second subject. Expulsion of the IUS has been reported in a total of 10 subjects (five LNG20, five Mirena). No deaths occurred in this reporting period. An interim review of all safety data reported as of December 2008 supports that LNG20 was generally well tolerated in female subjects with menorrhagia.
This study is being performed to evaluate the Medicines360 levonorgestrel-releasing IUS, LNG20. LNG20 is expected to provide safe and effective contraception for up to 7 years.
The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception.
The secondary objectives of this study are to assess:
• The safety, tolerability, bleeding patterns, and continuation rates of LNG20
• The occurrence of menses and return to fertility after IUS discontinuation
• The plasma pharmacokinetics of levonorgestrel in a subset of 80 subjects (40 for each IUS) with serial sampling over the duration of use
• Plasma levonorgestrel levels in a subset of approximately 60 subjects (LNG20 arm only) following IUS removal at 85 months of use with sampling at various timepoints up to 14 days post-IUS removal
• Plasma levonorgestrel levels for all subjects at each visit starting with Month 36 to support a decision for extended duration of use of LNG20 beyond Month 60
• Analysis of an appropriate sampling of IUSs that are removed and, when available, expelled during the study
• The safety and tolerability of LNG20 in a small cohort of women between ages 36 and 45 years
• Endometrial thickness in a subset of 60 subjects at 1, 5 and 7 years of LNG20 use
The Utah study site has been selected to participate in the PK Treatment substudy.
• Levonorgestrel PK data will be generated in a subset of 80 subjects, (approximately 40 subjects per study arm). Blood samples will be obtained at the Enrollment Visit (pre-IUS insertion), Weeks 1 and 2, and Months 1, 3, 6, 9, 12, 18, 24 and 30 after IUS insertion.
Principal Investigator: David Turok
Department: DFPM-Family Practice
Phone: (801) 213-2774